Athenex discloses patient death, clinical hold on CAR-NKT trial as it seeks strategic alternatives
A neuroblastoma patient has died after receiving Athenex’s natural killer cell therapy, triggering a clinical hold, the company revealed.
Baylor College of Medicine, which is running the trial, has identified some of the conditions leading up to the patient’s death and is “devising a safety risk mitigation plan” to reopen the trial, according to Athenex. It did not return requests for comment on when the patient’s death occurred.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters